Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009)
Támogató: EFOP-VEKOP
(739593) Támogató: Horizon 2020
(NTP-NFTÖ-20-B-0332)
Thiopurine-induced acute pancreatitis (TIP) is one of the most common adverse events
among inflammatory bowel disease patients treated with azathioprine (AZA), representing
a significant clinical burden. Previous studies focused on immune-mediated processes,
however, the exact pathomechanism of TIP is essentially unclear.To model TIP in vivo,
we triggered cerulein-induced experimental pancreatitis in mice receiving a daily
oral dose of 1.5 mg/kg AZA. Also, freshly isolated mouse pancreatic cells were exposed
to AZA ex vivo, and acinar cell viability, ductal and acinar Ca2+ signaling, ductal
Cl- and HCO3- secretion, as well as cystic fibrosis transmembrane conductance regulator
(CFTR) expression were assessed using microscopy techniques. Ras-related C3 botulinum
toxin substrate (RAC1) activity was measured with a G-LISA assay. Super-resolution
microscopy was used to determine protein colocalization.We demonstrated that AZA treatment
increases tissue damage in the early phase of cerulein-induced pancreatitis in vivo.
Also, both per os and ex vivo AZA exposure impaired pancreatic fluid and ductal HCO3-
and Cl- secretion, but did not affect acinar cells. Furthermore, ex vivo AZA exposure
also inhibited RAC1 activity in ductal cells leading to decreased co-localization
of CFTR and the anchor protein ezrin, resulting in impaired plasma membrane localization
of CFTR.AZA impaired the ductal HCO3- and Cl- secretion through the inhibition of
RAC1 activity leading to diminished ezrin-CFTR interaction and disturbed apical plasma
membrane expression of CFTR. We report a novel direct toxic effect of AZA on pancreatic
ductal cells and suggest that the restoration of ductal function might help to prevent
TIP in the future.